CFAP161

Across TCGA pan-cancer cohorts, CFAP161 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CFAP161 data layer compared with 21 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in stomach adenocarcinoma (STAD), where higher CFAP161 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CFAP161 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

STAD, LUSC, and UCEC are the cancer types where CFAP161 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
STAD	OS	Median	All	0.061	0.731	<.001	18	view →
LUSC	OS	Median	All	0.152	0.762	.001	12	view →
UCEC	DFS	Median	All	1.000	0.830	.022	8	view →
SKCM	DFS	Median	III,IV	0.087	0.647	.013	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CFAP161–STAD (OS)

Open the STAD breakdown →